Nie X, et al. - In view of the anticarcinogenic effect of transmembrane protein with epidermal growth factor-like and two follistatin-like domains 1 (TMEFF1) in brain tumors, researchers explored the part TMEFF1 plays in epithelial ovarian cancer (EOC). Compared to the normal ovary group and the borderline and benign tumor groups, the EOC group displayed higher TMEFF1 expression. Its high expression was significantly associated to International Federation of Gynecology and Obstetrics stage and was an independent predictor of shorter overall survival. The inhibition of TP53 led to downregulation of TMEFF1 protein expression in an ovarian cancer cell lines (CAOV3 and ES-2). According to chromatin immunoprecipitation (ChIP) assay, the transcription factor, p53, bound the promoter region of the TMEFF1 gene. These findings suggest that in ovarian cancer, TMEFF1 is a carcinogenic gene and it can be regulated by p53 transcription. TMEFF1 promotes the malignant behavior in EOC through MAPK and PI3K/AKT signaling pathways. Therefore, for ovarian cancer, they suggest considering TMEFF1 as a potential therapeutic target.